CLINICAL ROLE -
Sortilin Targeted Peptide-Drug Conjugates: A New Mechanism to Extend Clinical Benefit
Data suggest the therapy can induce prolonged clinical benefit, even after treatment discontinuation.
A Prevention Strategy for Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast Cancer May Be in Sight
There are currently no effective treatments for CIPN prevention.
Targeting Folate Receptor α Is Ideal for Ovarian Cancer Treatment
FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.
Vorasidenib Improves PFS in Grade 2 Gliomas With Manageable Safety Profile
Neither of the 2 current standards of care offers patients a cure.
Nivolumab-AVD Is Poised to Be New Standard of Care for Hodgkin Lymphoma in Adult and Pediatric Patients
The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.
Overall Survival Results Reinforce Osimertinib as Standard of Care for EGFRm Stage IB-IIIA NSCLC
Updated phase 3 trial data provide practice-changing findings.
Notable ASCO Trial Data Have the Potential to Transform Oncology Pharmacy Practice
These study results may inform clinical practice strategies this year and beyond.
2023 ASCO Data Leave Their Impact on Oncology Pharmacy
The American Society of Clinical Oncology (ASCO) Annual Meeting includes updates from some of the most important clinical trials being conducted in the field of oncology.
